Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan effects on pulmonary artery wall thickness in pulmonary arterial hypertension
ACTRN12606000289516Phase 4Not yet recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bosentan in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy and Scleroderma-associated pulmonary arterial hypertension (SSc-PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Change in pulmonary artery wall thickness and Change in pulmonary microvascular dilator response to acetylcholine. Planned start Jul 2006; status: not yet recruiting.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyScleroderma-associated pulmonary arterial hypertension (SSc-PAH)
Beyond the preview
Go deeper on ACTRN12606000289516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000289516.